Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of filgotinib in Crohn's disease
2016-002763-34Phase 3Completed
- Sponsor
- Galapagos NV
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in Crohn's disease, sponsored by Galapagos NV. Primary endpoint: Safety (adverse events, labs, vital signs). Started Dec 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-002763-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002763-34.